Therapy Escalation Thresholds and the Potential for Biased Cost Effectiveness Analysis When Failing to Sample Baseline HbA1c in Type 2 Diabetes
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.1651
https://www.valueinhealthjournal.com/article/S1098-3015(13)03556-0/fulltext
Title :
Therapy Escalation Thresholds and the Potential for Biased Cost Effectiveness Analysis When Failing to Sample Baseline HbA1c in Type 2 Diabetes
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)03556-0&doi=10.1016/j.jval.2013.08.1651
First page :
A592
Section Title :
Research on Methods Studies
Open access? :
No
Section Order :
1493